Tibetan Medicine Why The Transfer Of Research Results “worthless”
Beijing on February 22 announced on the Tibetan medicine, has a wholly owned subsidiary companies and four research results have to transfer 28 million yuan to the Beijing Sheng Hongsheng Technology Co., Ltd. property. Although the Tibetan medicine has repeatedly said the transfer was due to R & D product line shift in strategy will not change the company’s main business of the company’s continued viability, profit and asset situation of no significant impact. But investors are still difficult to understand the move, as pharmaceutical companies, pharmaceutical-related research to shift the transfer out. “Do real estate companies to work toward it? Tibetan medicine seems to have to continue to swing between the pharmaceutical and real estate will be ‘proper job’ for in the end.”
Late notice In yesterday’s announcement, Tibetan medicine, said the company and a wholly owned subsidiary in Chengdu Nuodikang biological Pharmacy Co., Ltd. has a recombinant human interleukin -1 receptor antagonist eye drops, recombinant human interleukin -1 receptor antagonist injection, Kangpuruiting disodium raw materials and freeze-dried preparation, salidroside lyophilized preparation of raw materials and research results of four projects, transfer of property to the Beijing Sheng Hongsheng Technology Co., Ltd., the transfer price of 28 million yuan by Beijing Shenghong Cheng received the above-mentioned four items related to debt.
Notice disclosure, the target of recombinant human interleukin -1 receptor antagonist eye drops being clinical trial of recombinant human interleukin -1 receptor antagonist injection clinical trial is starting, Hong Pu Ruiting disodium phosphate raw materials and freeze-dried preparation has applied for clinical trials permits, raw materials and freeze-dried preparation salidroside has applied for clinical trials permits. Tibetan medicine for more than four projects in development effort for the 24.71 million yuan.
Tibetan Medicine has repeatedly stressed that this transfer was due to R & D product line shift in strategy will not change the company’s main business of the company’s continued viability of gains and losses and asset situation of no significant impact.
In fact, the Tibetan medicine as early as February 11 and Chengdu on Nuodikang Biological Pharmaceutical Co., Ltd. (hereinafter referred to as “Chengdu Nuodikang”), Beijing Sheng Hongsheng Technology Co., Ltd. property (hereinafter referred to as “Beijing Morihiro” ) signed a new drug projects and research results on the transfer of “technology transfer contract,” and in the Feb. 12 meeting of the board of directors unanimously adopted the “transfer contract”, the contract currently in force. The late announcement of the time seems not less.
Controlling uncertain struggle? Tibetan medicine control of major shareholders have already two years long struggle, the “transfer contract” board of directors unanimously approved by the Company, are among the major shareholders have shifted from confrontation Cooperation A?
Public information, Tibetan medicine market in 1999, West Pharmaceutical is one of five founders. At present, Tibetan medicine for the 13,871 shares of total equity. 2007, Tibet medicine at a loss, to ensure the company’s continuing operations, the major shareholder of the Tibetan medicine in Tibet to the Beijing West China Pharmaceutical Group, the new Phoenix real estate purchase some shares. Phoenix
into Tibet in the new medicine, the Tibetan medicine has been the concept of real estate investors as the potential for stocks, after two years, the company has been wavering in between Tibetan medicine and real estate, a major shareholder the struggle for a controlling stake to mark the opening.
The second half, West China Pharmaceutical Group held 6,000,000 shares Tibetan medicine for auction three times, has been stopped three times. If the successful auction of 600 million shares, West China Pharmaceutical Group major shareholder in Tibet medicine, will also be competition for control of its two years of the second-largest shareholder replaced by the new Phoenix. Therefore, 600 million shares on a controlling stake in maintaining the status of West Pharmaceutical scene.
Tibetan medicine first, the second largest shareholding proportion. 2009 semiannual reports show the company’s largest shareholders, holding Tibetan Medicine 3148 West Pharmaceutical shares, accounting for 22.69 percent; the second-largest shareholders, holding Phoenix Beijing 2696 new shares, accounting for 19.44 percent, but the new Phoenix City and Zhou Mingde, Qin Si concerted action such as the control of up to 3353 million shares, more than the West Pharmaceutical. If the West Pharmaceutical be “lost” 600 million shares, then the influence of its board of directors will be reduced.
I am China Quality Dress writer, reports some information about bg sprayers , stainless soap pump.
Processing your request, Please wait....
